Positive News SentimentPositive NewsNASDAQ:ELUT Elutia (ELUT) Stock Price, News & Analysis $3.26 +0.06 (+1.84%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Elutia Stock (NASDAQ:ELUT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Elutia alerts:Sign Up Key Stats Today's Range$3.05▼$3.2950-Day Range$2.55▼$3.4052-Week Range$2.28▼$5.24Volume79,846 shsAverage Volume45,276 shsMarket Capitalization$113.02 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company OverviewElutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Read More… Remove Ads Elutia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreELUT MarketRank™: Elutia scored higher than 82% of companies evaluated by MarketBeat, and ranked 175th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingElutia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageElutia has only been the subject of 1 research reports in the past 90 days.Read more about Elutia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Elutia are expected to grow in the coming year, from ($1.74) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elutia is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elutia is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Elutia's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.29% of the float of Elutia has been sold short.Short Interest Ratio / Days to CoverElutia has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elutia has recently decreased by 29.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElutia does not currently pay a dividend.Dividend GrowthElutia does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.29% of the float of Elutia has been sold short.Short Interest Ratio / Days to CoverElutia has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elutia has recently decreased by 29.77%, indicating that investor sentiment is improving significantly. News and Social Media3.7 / 5News Sentiment1.59 News SentimentElutia has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Elutia this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Elutia to their MarketBeat watchlist in the last 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Elutia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,050,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders40.80% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Elutia's insider trading history. Receive ELUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elutia and its competitors with MarketBeat's FREE daily newsletter. Email Address ELUT Stock News HeadlinesElutia Inc. (NASDAQ:ELUT) Director Acquires $1,050,000.00 in StockMarch 14, 2025 | insidertrades.comElutia files $100M mixed securities shelfMarch 18 at 9:04 AM | markets.businessinsider.comYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.March 18, 2025 | American Alternative (Ad)Elutia Inc. Q4 Loss DecreasesMarch 8, 2025 | nasdaq.comEarnings call transcript: Elutia Q4 2024 misses forecasts, stock dropsMarch 8, 2025 | uk.investing.comElutia Inc. (NASDAQ:ELUT) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comQ4 2024 Elutia Inc Earnings CallMarch 7, 2025 | finance.yahoo.comElutia reports Q4 EPS (26c) vs. (40c) last yearMarch 7, 2025 | markets.businessinsider.comSee More Headlines ELUT Stock Analysis - Frequently Asked Questions How have ELUT shares performed this year? Elutia's stock was trading at $3.74 on January 1st, 2025. Since then, ELUT stock has decreased by 12.6% and is now trading at $3.27. View the best growth stocks for 2025 here. How were Elutia's earnings last quarter? Elutia Inc. (NASDAQ:ELUT) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.19. The business earned $11.49 million during the quarter, compared to the consensus estimate of $11.54 million. Who are Elutia's major shareholders? Top institutional shareholders of Elutia include AIGH Capital Management LLC (8.90%), Silverarc Capital Management LLC (5.16%), Birchview Capital LP (3.55%) and Kennedy Capital Management LLC (0.54%). Insiders that own company stock include Highcape Capital, LP, Birchview Capital, Lp, Matthew Ferguson, Thomas Englese, David Colpman and Brigid Makes. View institutional ownership trends. How do I buy shares of Elutia? Shares of ELUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Elutia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elutia investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Jabil (JBL), Meta Platforms (META) and ServiceNow (NOW). Company Calendar Last Earnings11/08/2021Today3/18/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELUT CIK1708527 Webwww.elutia.com Phone240-247-1170Fax510-307-9896Employees180Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+181.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,660,000.00 Net Margins-218.72% Pretax Margin-243.28% Return on EquityN/A Return on Assets-142.61% Debt Debt-to-Equity RatioN/A Current Ratio0.94 Quick Ratio0.85 Sales & Book Value Annual Sales$24.38 million Price / Sales4.54 Cash FlowN/A Price / Cash FlowN/A Book Value($1.66) per share Price / Book-1.93Miscellaneous Outstanding Shares34,562,000Free Float20,461,000Market Cap$110.60 million OptionableNot Optionable Beta0.86 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ELUT) was last updated on 3/18/2025 by MarketBeat.com Staff From Our PartnersIs this the End of the AI Boom?If you’re worried about all the recent volatility in the market… Or if you have any money in AI stocks… ...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredFormer CIA to Trump – Will you Shut down this secret lab?Deep in the sands of New Mexico lies a government lab so secret it makes Area 51 look like a tourist spot… ...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMusk’s real agenda in D.C. Companies connected to Elon’s new map of America are making major climbs in price. And on May 30, the next wav...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.